Study Overview: This study checks how safe and effective a new drug, **DF6002**, is when used alone or with another drug called Nivolumab. It focuses on people with serious forms of cancer called advanced solid tumors, which are large groups of cancer cells that have spread in the body.
Who Can Join: To be part of this study, you must have an advanced solid tumor, like lung, skin, or breast cancer, and no other treatment options. You need to be healthy enough to do daily activities (ECOG score of 0 or 1), and have good blood, liver, and kidney health. You might need blood thinners if you have a history or risk of blood clots.
Who Cannot Join: You can't join if you're getting other cancer treatments, have had another cancer in the past 3 years (except certain skin, prostate, or cervical cancers), or have serious heart issues.
- Duration: The study length is not specified, but it involves several visits.
- Risks: Possible side effects from the drugs or treatments.
- Compensation: May be provided for participation.